Natural killer (NK) cells are innate effectors, which play a crucial role in controlling 26 viral infections. Administration of IFN-α has shown promising results as a therapeutic, 27 controlling HIV, and chronic viral hepatitis. However the downstream mechanisms by which 28 IFN-α mediates its anti-viral effects is largely unknown. In this investigation, we evaluated 29 the impact of IFN-α on peripheral blood NK cells from healthy donors. High dimensional 30 flow cytometry analysis of NK cell surface receptors following exposure to IFN-α showed an 31 increased expression of the check point inhibitor LAG3. Further characterization revealed 32 that LAG3 was expressed in a subset of NK cells with high expression of activation and 33 maturation markers. Assessment of metabolic pathways showed that LAG3+ NK cells had 34 enhanced rates of glycolysis and glycolytic capacity, suggesting that it is a primed effector 35 subset with enhanced glucose metabolism. Inhibition of LAG3 on NK cells using antibody in 36 vitro resulted in a profound increase in secretion of cytokines IFN-γ, TNF-α, MIP-1α and 37 MIP-1β, without affecting the cytotoxic activity. Taken together, these results showed that 38 LAG3 is a negative regulator of cytokine production by mature NK cells. 39 40 Introduction: 41 2 The plasmacytoid (pDC)-Natural Killer (NK) cell axis acts as a first line of defence by the 42 host against viral infections. pDCs secrete type I interferons upon recognizing virus-43 associated pathogen associated molecular patterns (PAMPs) through pattern recognition 44 receptors (PRRs). Type I interferons (IFN-I) bind to IFN (IFN-/) receptors on the surface 45 of NK cells to prime, activate and initiate mechanisms for the destruction of infected cells. 46 The subsequent stimulation of the IFN signalling pathway results in the increased expression 47 65 expression of LAG3, an inhibitory receptor, commonly associated with T cell exhaustion in 66 chronic infections and cancer. To date, the function of LAG3 in NK cells is not well 67 understood due to contrasting results from mouse and human NK cells. While studies using 68 knockout mouse models suggested a positive role for LAG3 in NK cell cytotoxicity, these 69 could not be successfully reproduced in human NK cells (10,11). High dimensional flow 70 cytometry analysis in these studies revealed that LAG3 expression marks a subset of mature 71 activated NK cells. Metabolic assays additionally showed that NK cells expressing LAG3 72 have enhanced glycolytic activity. Blockade of LAG3 enhanced cytokine production by 73 activated NK cells without altering their cytotoxicity. Taken together, these results 74 demonstrate that LAG3 is a negative regulator of cytokine production and a potential 75 therapeutic target for chronic viral infections. 76 77 78 3 Materials and methods: 79 Isolation and stimulation of NK cells: Blood samples from healthy volunteer donors were 80 obtained after approval by the National Healthcare Group Domain Specific Review Board, 81 Singapore (NHG DSRB Ref: 2000/00828). Samples were collected after getting written 82 consents from volunteers. PBMCs were isolated from blood by Ficoll density gradient 83 centrifugation (Ficoll-Paque, GE Healthcare). NK cells were isolated using the NK cell 84 isolation kit (Miltenyi Biotec) following the manufacturer's protocol. Purity was 94% to 85 99%, confirmed by flow cytometry using the markers, CD3 and CD56. Isolated NK cells 86 were stimulated for 16 hours in vitro with recombinant IL-2 (100 U/ml) or recombinant IFN-87 α (10 ng/ml) or a combination of both, in Iscove's Modified Dulbecco's Medium (IMDM, 88 Gibco) supplemented with 10% FBS, 100U/ml penicillin, 100 g/ml streptomycin, 1mM 89 pyruvate, 2mM L-glutamine, nonessential amino acids and 15mM HEPES (complete 90 (cIMDM)). Cells left untreated in medium alone were used as a negative control. For flow 91 cytometry analysis, PBMCs were stimulated for different time periods up to 96 hours, as 92 described in the figure legends. 93 NK cells were expanded by culturing with IFN-α and IL-2 (Miltenyi Biotec) in cIMDM for 94 48 hours to induce priming. They were then co-cultured with genetically modified K562 95 cells, expressing 4-1BBL, membrane bound IL-21 and CD86 (TD reference number 96 GIS/Z/10345) (28), at a ratio of 1:1 (NK:K562) in cIMDM with IL-2 (100 U/ml) and IL-15 97 (10 ng/ml) for up to 3 weeks. Fresh medium containing IL-2 and IL-15 was added to the cells 98 every 3 days. The cells were then washed, counted, stained and sorted as described below. 99 RNA isolation and gene expression analysis: The cells were washed in PBS and the cell pellet 100 was lysed in RLT lysis buffer containing -Mercapto Ethanol and stored at -80ºC. Total RNA 101 was extracted from cell lysates using RNeasy Mini Kit (Qiagen, Valencia, CA, USA), 102 according to the manufacturers' instructions. Total RNA (50ng/hybridization reaction) was 103 used to analyze the immune gene expression profile in NK cells using the nCounter® Human 104 Immunology v2 Panel (NanoString Technologies, Seattle, WA, USA). This technology relies 105 on the direct hybridization of total RNA with fluorescent barcoded probes complementary to 106 579 immune response-related genes and 15 internal reference controls. The hybridized probes 107 were purified and counted on the nCounter® SPRINT Profiler (NanoString Technologies). 108 Data was analysed with the nSolver 4.0 software (NanoString Technologies). After 109 subtracting background noise (calculated as the mean plus 2 SD of the negative control 110 probes, excluding outliers), intra-/inter-assay variability was adjusted according to the signal 111 of the positive control probes. The data were normalized against the ratio between the 112 geometric mean of all positive controls and the geometric mean of the positive controls of 113 each sample. The samples were then normalized for RNA content according to the relative 114 expression of the housekeeping genes provided in the assay. 115 Antibodies and flow cytometry: The following antibodies were used in NK cell flow 116 cytometry panel; CD56 PE
of several interferon stimulated genes (ISGs) which have direct and indirect antiviral 48 activities (1). 49 In chronic viral infections, such as hepatitis B, or C virus (HBV or HCV 50 respectively), NK cells demonstrate reduced cytotoxicity and cytokine secretion (2,3) 51 Additionally, a reduction in circulating numbers of NK cells has been observed (2), together 52 with reduced levels of their activating receptors (4). Type I interferons produced during a 53 viral infection and cytokines, such as IL-12, IL-15 and IL-18, prime NK cells to enhance their 54 cytotoxic and cytokine secretory functions (5) . Therapeutic administration of PEGylated-55 IFN-α results in loss of HBsAg, a hallmark of functional cure in chronic HBV patients (6) . 56 IFN-α therapy resulted in increased surface expression of activating receptors on NK cells, 57 including NKp46, TRAIL. NK cells also showed restored cytotoxicity and production of 58 IFN (7-9). Taken together, these studies strongly support a direct role for NK cells in 59 controlling viral infections mediated by IFN-α stimulation. 60 NK cells express a wide variety of activating and inhibitory receptors and their 61 function is determined by the balance between positive and negative signaling from these 62 receptors. It is crucial, therefore, to understand the phenotype of different NK cell subsets 63 during disease and treatment. We aimed to directly ascertain the phenotypic and functional 64 changes induced in NK cells following IFN-α stimulation. Exposure to IFN-α induced the optimal dilutions prior to panel integration. Single SIgN, A*STAR) was added to NK cells (10 ug/ml) and target cells and proceeded with assay 147 as above. 
Interferon- induces LAG3 mRNA expression in NK cells: 163
Little is known about the mechanism behind enhanced NK responses upon priming with 164 IFNα. To unravel this, NK cells were isolated from healthy donor PBMCs and then cultured 165 with IFN-α in the presence or absence of IL-2. The latter was added to maintain the survival 166 of NK cells. After 16 hours, gene expression was analysed using Nanostring. The presence of 167 IFN-α resulted in the induction of a distinct set of genes compared to IL-2 stimulation alone 168 ( Fig 1a) . As expected, known IFN-α inducible genes, which included MX1, IFIT2, IFI35, 169 IFITM1 and IFIH5, were upregulated in this group ( Fig 1A) . Importantly, the expression of 170 5 the NK cell activating receptors, TRAIL and SLAMF7, were increased in response to IFN-α 171 ( Fig 1B and C) . Analyses of inhibitory receptors revealed that among all the inhibitory 172 receptors, LAG3 mRNA was uniquely upregulated among all the other inhibitory receptors 173 measured in response to IFN-α ( Fig 1B and C) . Expression of LAG3 mRNA was 15 fold 174 more than the average expression of TIM3, the second most upregulated inhibitory receptor, 175 induced by IL-2 and IFN-α. These results showed that LAG3 gene expression is induced by 176 IFN-α in NK cells.
177
NK cells upregulate surface expression of LAG3 following IFN-α exposure: 178 We went on to examine the expression of LAG3 at single cell level. PBMCs from healthy 179 donors were stimulated with IFN-α in the presence or absence of IL-2 for various time Figure 3A ). The increased expression of CD57 and CD158b suggested that LAG3+ NK cells 205 are more mature than LAG3-NK cells (15) and elevated surface expression of TIM3 206 indicated that LAG3+ NK cells were activated (16).
207
Further characterization using the UMAP dimensionality reduction algorithm revealed 208 that LAG3 expression was on multiple NK cell subsets ( Fig 3B) . Heat map analysis of 209 phenograph clusters indicated that LAG3 was expressed predominantly on CD57+ mature 210 NK cells ( Fig 3C) . These clusters formed the majority of LAG3 expressing subsets, and also 211 co-expressed the activating receptors CD319, NKG2C, CD226 and CD38 and the inhibitory 212 receptor TIM3 (Fig 3C and Supp. Figure 3B ). LAG3 expression was also observed on a small 213 population of NK cells expressing lower levels of CD57 and higher levels of PD-1 and TIM3, 214 which are considered to be markers of T cell exhaustion. These results confirmed that LAG3 215 expression is associated with NK cell activation and maturation. 
LAG3 expression defines a subset of NK cells with increased glycolytic activity:
217 Metabolic reactions play a key role in defining immune cell function. Therefore, we went on 218 to evaluate real-time metabolic flux on sorted LAG3+ and LAG3-NK cell subsets using a 219 Seahorse Analyzer. LAG3+ NK cells exhibited higher glycolytic function compared to 220 LAG3-NK cells (Fig. 4A) . Specifically, LAG3 expressing NK cells had higher rate of 221 glycolysis and higher glycolytic capacity than LAG3-NK cells (Fig. 4B-C) . Both indicate 222 enhanced utilization of glycolytic pathway in the LAG3+ cells. No significant differences 223 were observed for glycolytic reserve and non-glycolytic acidification between the LAG3-and 224 LAG3+ subsets (Supp. Fig 4) . Furthermore the OCR was similar between the two subsets, 225 indicating no change in the oxidative phosphorylation pathway (Supp. Fig 4B) . These results 226 indicate that LAG3 expression defines a subset of NK cells that are more glycolytically active 227 compared to LAG3-NK cells. 229 An earlier study found that mice lacking LAG3 in NK cells were incapable of killing target 230 cells, suggesting a critical role for LAG3 in cytotoxic function (10). However, the function of 231 LAG3 in human NK cells remains unclear (11). Therefore, to assess its role in cytotoxicity,
228

LAG3 is a negative regulator of NK cell cytokine production:
232
NK cells were isolated from PBMCs, primed with IFN-α / IL-2 and then expanded in vitro 233 for 3 weeks. These NK cells were cultured with target cells loaded with Calcein-AM dye at 234 different effector to target ratios for 5 hours in the presence of a LAG3 blocking antibody, or 235 isotype control, and the cytotoxicity was measured by the fluorescence of Calcein dye 236 released into the medium upon target cell lysis. Blocking LAG3 did not have any effect on 237 the killing activity of NK cells (Fig 5a) . However analysis of cytokine secretion revealed an 238 increase in the production of IFN, TNF, MIP1, MIP1 and GM-CSF by NK cells when 239 they were cultured in the presence of anti-LAG3 blocking antibody compared to control IgG 240 (Fig 5b) . These results demonstrate that LAG3 has a negative regulatory effect in NK cell 241 production of cytokines without significantly affecting their cytotoxic function.
243
Discussion: 244 In this study we have established that LAG3 plays a central role in regulating NK cell 245 cytokine production. We also showed that IFN-α rapidly induces the expression of the LAG3 246 inhibitory receptor on NK cells. Using high dimensional flow cytometry, we characterised 247 LAG3+ NK cells to be both mature and activated based on their expression of CD57, 248 NKG2C and TIM3. Furthermore, LAG3 expressing NK cells also had enhanced glycolytic 249 capacity suggesting a metabolically mature phenotype. Finally, we demonstrated that LAG3 250 is unique in its ability in selectively regulating inflammatory cytokine secretion and not 251 cytotoxicity. Taken together, these results conclusively characterise the phenotype and 252 function of LAG3 in activated human NK cells. mRNA by 16 hours. This is in keeping with earlier work demonstrating an increase in LAG3 262 mRNA and several ISGs in NK cells as early as 6 hours after stimulation with IFN-α 263 suggesting that LAG3 is one of the early expressed genes in response to IFN-α stimulation on 264 NK cells (17).
265
NK cells are a diverse effector population that vary both in phenotype and function.
266
High dimensional flow cytometry analyses used in our study revealed that LAG3+ NK cells 267 had a higher expression of CD57, a known maturation marker (18). Our analysis also showed 268 that LAG3+ cells expressed increased levels of NKG2C, an activation receptor found to be 269 enhanced in chronic viral infections (18, 19) . Previous studies have shown that activation, idea that its function is to attenuate the cytokine production of mature CD56low NK cells 280 without affecting their killing ability.
281
Previous work has shown that LAG3 is check point inhibitory receptor expressed on 282 exhausted cytotoxic T cells (24, 25) . NK cells expressing NKG2C and CD57 were described 283 following chronic stimulation of activating receptors. These exhibited an exhausted 284 phenotype and co-expressed PD-1, TIM3 and LAG3 (26, 27) . In our analysis a small subset of 
